Soon after KJ Muldoon was born in the summer of 2024, he was diagnosed with a rare genetic disorder that is fatal for about half the infants who are born with it.
Until now, the only effective long-term treatment for the rare metabolic disease known as severe Carbamoyl Phosphate Synthetase 1 deficiency, or CPS1, had been a liver transplant.
Instead, doctors at the Children’s Hospital of Philadelphia told KJ’s family they could try something never done before. They would use a technology known as CRISPR, a personalized gene-editing therapy, to find the one uniquely mutated gene out of 20,000 in his little body, and fix it.
He became the first known patient in the world to be treated using CRISPR personalized just for him, according to a news release from Penn Medicine. His case was published Thursday in the New England Journal of Medicine.
I mean the alternative was a liver transplant, and I have no idea how an infant liver transplant would even work. The only way doctors and researchers were ethically going to be able to treat someone with CRISPR is exactly this kind of situation
Organ transplants for infants typically come from other infants. The ones that have organs to spare are the ones that are functionally dead for other reasons. I used to work at a children’s hospital in the ER and I’ve seen multiple infants end up brain dead from trauma and someone had to ask the family if they would donate their child’s organs to save other children.